RE: Nasdaq/US exchanges I agree with some of your post regarding uplisting to US exchanges however how is uplisting an answer to weak share prices? Minimum thresholds in share price have to be met before an uplisting is considered for a company among other requirements. Nasdaq is $2 so if BNC were to be there for any amount of time that would be considered strength for its sp.
The main thing here is that many biotechs just don't have the pipeline BNC possess. Sooner or later BNC will have to make that jump to the next level.